• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Varenicline may be a viable option in the future for vaping cessation

byRhianna DavisandAlex Chan
July 12, 2023
in Chronic Disease, Public Health, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Varenicline, in addition to counseling, increased e-cigarette cessation at 12 and 24 weeks compared to counseling alone. 

Evidence Rating Level: 2 (Good)

There are currently no evidence-based recommendations to guide e-cigarette (EC) cessation. Given that EC use is increasing worldwide, the number of patients turning to clinicians for guidance on cessation is likely to increase. Researchers aimed to evaluate the effectiveness of varenicline for EC cessation. 140 participants interested in EC cessation were randomized into two groups. One group received 1 mg varenicline twice per week for 12 weeks, in addition to counseling. The second group received a placebo treatment twice weekly for 12 weeks, in addition to counseling. Participants were followed for an additional 12 weeks after the end of treatment. The primary study endpoint was abstinence from weeks 4-12. They also assessed continued abstinence during the follow-up period. Continuous abstinence was significantly higher in the varenicline group compared to placebo at weeks 4-12 (OR, 2.67; 95% CI, 1.25–5.68; P=0.011) and weeks 4-24 (O,R,2.52; 95% CI, 1.14–5.58; P=0.0224). This randomized control trial indicates that including varenicline as part of an EC cessation plan may improve abstinence. This study may be helpful to guide clinicians counseling patients on EC cessation. Limitations of the study include the small sample size and short follow-up period. Future research may assess whether varenicline is beneficial for long-term EC cessation. It also remains to be determined whether varenicline alone, without counseling, is beneficial for EC cessation. Nonetheless, study results may reflect a novel research field investigating viable evidence-based recommendations for e-cigarette smoking cessation. 

Click to read the study in BMC Medicine

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: Higher Nicotine Consumption Observed Among Youth with Attention-Deficit-Hyperactivity Disorder

Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer:

Higher nicotine consumption observed among youth with attention-deficit hyperactivity disorder

Tags: cigarettese-cigarettessmokingsmoking cessationvaping
Previous Post

Dose-escalated simultaneous integrated boost radiotherapy may increase ipsilateral breast tumor relapse rates

Next Post

Wellness Check: Sleep

RelatedReports

#VisualAbstract: Higher Nicotine Consumption Observed Among Youth with Attention-Deficit-Hyperactivity Disorder
StudyGraphics

#VisualAbstract: Higher Nicotine Consumption Observed Among Youth with Attention-Deficit-Hyperactivity Disorder

April 16, 2025
No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer
Cardiology

Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer:

April 13, 2025
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Higher nicotine consumption observed among youth with attention-deficit hyperactivity disorder

May 19, 2025
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Characterization of increased cryptogenic ischemic stroke risk from smoking

May 19, 2025
Next Post
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Wellness Check: Sleep

Smoking during pregnancy associated with aerobic fitness of children

Patterns and characteristics of nicotine dependence among adults with cigarette use in the United States between 2016 and 2019

The 2 Minute Medicine Podcast Episode 15

The 2 Minute Medicine Podcast Episode 19

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
  • Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.